REFERENCES
- Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ, Navickis RJ. Augmentation therapy for a1 antitrypsin deficiency: A meta-analysis. COPD: J Chron Obstruct Pulmon Dis 2009; 6(3):177–184.
- Vreim CE, Wu M, Crystal RG, Buist AS, Burrows B, Cohen AB, Survival and FEV1 decline in individuals with severe deficiency of a1-antitrypsin. Am J Respir Crit Care Med 1998; 158(1):49–59.
- Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, Does alpha12-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Eur Respir J 1997; 10:2260–2263.
- Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DCS, Ulrik CS, A randomized clinical trial of a1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999; 160(5):1468–1472.
- Wencker M, Fuhrmann B, Banik N, Konietzko N, Wissenschaftliche A. Longitudinal follow-up of patients with a1-protease inhibitor deficiency before and during therapy with IV a1-protease inhibitor. Chest 2001; 119(3):737–744.
- Wewers MD, Casolaro MA, Sellers SE, Swayze SC, McPhaul KM, Wittes JT, Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987; 316:1055–1062.
- Dirksen A, Piitulainen E, Parr DG, Deng C, Wencker M, Shaker SB, Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33(6):1345–1353.
- Soriano JB, Miravitlles M. Your racing horses will help you to quit: a lesson for COPD and alpha1-antitrypsin deficiency research. Eur Respir J 2009; 33(6):1244–1246.
- Wencker M, Banik N, Buhl R, Seidel R, Konietzko N. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1- AT-study group. Eur Respir J 1998; 11(2):428–433.
- Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359(15):1543–1554.
- Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356(8):775–789.
- Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: Results from the TORCH study. Am J Respir Crit Care Med 2008; 178(4):332–338.
- Decramer M, Celli B, Tashkin DP, Pauwels RA, Burkhart D, Cassino C, Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: The UPLIFT trial. COPD 2004; 1(2):303–312.